• 1

Place and Track Orders with RxConnect   login-rx   NEW ACCOUNT »

divider-2

SynergEyes is committed to complying with the Sunshine reporting provisions of the Patient Protection and Affordable Care Act of 2010 (the “Affordable Care Act”), which requires that all manufacturers of drugs, devices, biological or other medical supplies collect and report data  concerning “transfers of value” to US Eye Care Professionals (ECPs) and identified teaching hospitals. The main purpose of the law is to provide patients with enhanced transparency into the relationships their health care providers have with life science manufacturers. It is important to note that the law does not restrict this collaboration or prohibit payments or transfers of value. Rather, it requires tracking and reporting by manufacturers of such payments or transfers or value by manufacturers.

Data collection was required to begin on August 1, 2013 and data collected must be reported to the Center for Medicare and Medicaid Services (CMS) no later than April 1, 2014, and annually thereafter. CMS will then post this information on its website for review by the public after a period of advance review is provided.

Types of transfers of value or payments provided by our company that must be reported include:

  • Food or drinks
  • Gifts or trinkets
  • Entertainment
  • In Kind gifts or services
  • Travel (air/hotel)
  • Education Reimbursement
  • Charitable contributions
  • Samples or No-Charge Product (if for sale to patient)
  • Royalties/Licenses
  • Ownership interest in our company
  • Honoraria
  • Educational reimbursement
  • Clinical study/research grants
  • Compensation provided for serving as faculty or a speaker at a medical education program

All transfers of value or payments with a value of $10 or more per item or a total of $100 per year must be reported.

In 2014, CMS will notify Covered Recipients that their individual data, as reported by all manufacturers, is available for review on a secure CMS website portal and that they will have 45 days to request corrections or modifications by contacting the manufacturer. An additional 15-day period will be provided after the initial 45-day review period to allow Manufacturers to resolve discrepancies reported by Covered Recipients.  If the issue remains unresolved, the data will be posted on the publicly accessible CMS website as reported by the manufacturer, with a notation indicating that the information is being disputed.

If you have any questions or concerns about a payment we report, please feel free to contact us via email at: This email address is being protected from spambots. You need JavaScript enabled to view it..

En esta farmacia www.med-farmacia.com usted será capaz de comprar las pastillas a un precio accesible.